

DEC 15 2003

**510(K) SUMMARY**

**AccuSoft**

**510(k) Number K** 032171

**Applicant's Name:**

Direx Systems Corp.  
11 Mercer Road, Natick Business park  
Natick, MA 01760  
United States of America  
Tel: (508) 6510900  
Fax: (508) 6518125

**Contact Person:**

Larisa Gershtein  
Direx Systems Corp.  
11 Mercer Road  
Natick, MA 01760  
Tel: (888) 874 7837  
Fax: (508) 651-8125  
E-mail: lgershtein@direxusa.com

**Trade Name:**

*AccuSoft™*

**Model:**

*AccuSoft*

**Classification Name:**

System, Planning, Radiation Therapy Treatment

**Classification:**

The FDA has classified this type of devices as class II (product code 90 IYE, Regulation No. 892.5050) and they are reviewed by the Radiology Panel.

**Predicate Devices:**

PerMedics' OptiRad k993895

**Performance Standards:**

No performance standards have been established for such device under Section 514 of the Federal Food, Drug, and Cosmetic Act.

However, *AccuSoft* complies with the following voluntary standards:  
Guidance for FDA Reviewers and Industry – Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.  
IEC 601-1-4, Medical electrical equipment – Part 1: General requirements for safety – 4. Collateral Standard: Programmable electrical medical systems.”

FDA/CDRH/ODE Draft Document - Guidance for Off-the-Shelf Software Use in Medical Devices (June 4, 1997).

EN 1441 (1997) - Medical Devices: Risk analysis;

Collateral Standard: Programmable electrical medical systems and IEC 60812 (1985) - Failure Mode and Effects Analysis.

**Intended Use:**

*AccuSoft* is intended to be used for the computation, display, evaluation, and output documentation of radiation dose estimations that are to be submitted for independent clinical review and verification by a physicist or physician prior to use.

The application provides output data in the form of displays or hardcopy printouts to guide a physician in selecting the optimum patient treatment plan. It is intended to provide a report to be used by a competent health professional such as a radiation oncologist, medical physicist, radiation therapist or dosimetrist.

**Device Description:**

*AccuSoft* is a radiation treatment planning system. It consists of a software package that executes accepted algorithmic approaches to produce radiation dose estimations and of extensive verification and quality assurance (QA) procedures to enable the proper system and patient setup and adequate radiation delivery. It includes the same image acquisition, localizing, delineation and beam planning techniques. *AccuSoft* is designed with stationary or “static” radiation beams. These beams can be shaped with a shaping device, a Micro-Multi-Leaf Collimator (MMLC), such that the shape of the radiation beam conforms to the irregular shape of the lesion. The ability to shape the radiation beam enables the user to treat irregularly shaped lesions, maximizing the radiation dose to the lesion, while minimizing the radiation dose to the surrounding normal tissue and critical structures.

**Substantial Equivalence:**

Based on validations and performance testing results, Direx Systems Corp. believes that *AccuSoft* is substantially equivalent to the predicate device cited above without raising new safety and/or effectiveness issues.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

DEC 15 2003

Ms. Larisa Gershtein  
QA Manager  
DiREX Systems Corporation  
11 Mercer Road  
NATICK MA 01760

Re: K032171  
Trade/Device Name: AccuSoft  
Regulation Number: 21 CFR 892.5050  
Regulation Name: Medical charged-particle  
radiation therapy system  
Regulatory Class: II  
Product Code: 90 IYE  
Dated: November 6, 2003  
Received: November 10, 2003

Dear Ms. Gershtein:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

### INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K032171 by Direx

Device Name:

*AccuSoft*

Indications for Use:

AccuSoft is to be used for the computation, display, evaluation, and output documentation of radiation dose estimations to be submitted for independent clinical review and judgment by a physicist or physician prior to use. The device provides output data in the form of displays or hardcopy printouts to guide a physician in selecting the optimum patient treatment plan. It is intended to provide a report to be used by a competent health professional such as a radiation oncologist, medical physicist, radiation therapist or dosimetrist.

(PLEASE DO NOT WRITE BELOW THIS LINE -CONTINUE ON ANOTHER PAGE IF NEEDED)

Prescription Use ✓

*David A. Agnew*

(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K032171